Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Prostatic Neoplasms 22 Breast Neoplasms 21 Polycystic Ovary Syndrome 12 Carcinoma, Non-Small-Cell Lung 11 Colorectal Neoplasms 10 Lung Neoplasms 8 Endometrial Neoplasms 7 Pancreatic Neoplasms 6 Neoplasms 6 Glioblastoma 5 Rectal Neoplasms 4 Melanoma 4 Lymphoma, Large B-Cell, Diffuse 4 Insulin Resistance 4 Adenocarcinoma of Lung 4 Adenocarcinoma 4 Uterine Cervical Neoplasms 3 Leukoplakia, Oral 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Obesity 2 Neoplasm Metastasis 2 Liver Neoplasms 2 Leukemia, Myeloid, Acute 2 Hyperandrogenism 2 Esophageal Neoplasms 2 Erythroplasia 2 Endometrial Hyperplasia 2 Diabetes Mellitus 2 Colonic Neoplasms 2

Interventions

lutetium Lu 177 dotatate 15 Everolimus 11 Nivolumab 10 pembrolizumab 9 Temozolomide 9 Capecitabine 7 cabozantinib 6 Sunitinib 6 lenvatinib 5 lanreotide 4 gallium Ga 68 dotatate 4 Ipilimumab 4 Etoposide 4 Carboplatin 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 telotristat ethyl 3 pazopanib 3 avelumab 3 Octreotide 3 Magnetic Resonance Spectroscopy 3 Injections 3 Cyclophosphamide 3 Cisplatin 3 Bevacizumab 3 surufatinib 2 sintilimab 2 fosbretabulin 2 fludarabine 2 Specimen Handling 2 Sorafenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neuroendocrine Tumors × Metformin × Clear all

NCT02279758 2014-10-31

MetNet

Instituto do Cancer do Estado de São Paulo

Phase 2 Unknown

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡